TY - JOUR
T1 - Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer
T2 - An Update on Literature with Case Presentation
AU - Nguyen, Nghi C.
AU - Shah, Muhammad
AU - Appleman, Leonard J.
AU - Parikh, Rahul
AU - Mountz, James M.
N1 - Publisher Copyright:
© 2016 Nghi C. Nguyen et al.
PY - 2016
Y1 - 2016
N2 - Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC. Clinical trials are currently investigating Radium-223 in additional clinical settings such as earlier asymptomatic disease and in combination with other agents including hormonal therapeutic agents and immunotherapeutic as well as chemotherapeutic agents. Trials are also ongoing in patients with other primary cancers such as breast cancer, thyroid cancer, and renal cancer metastatic to bone. In this article, the physics and radiobiology, as well as a literature update on the use of Radium-223, are provided along with case presentations, aiming at a better appreciation of research data as well as the assimilation of research data into clinical practice.
AB - Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC. Clinical trials are currently investigating Radium-223 in additional clinical settings such as earlier asymptomatic disease and in combination with other agents including hormonal therapeutic agents and immunotherapeutic as well as chemotherapeutic agents. Trials are also ongoing in patients with other primary cancers such as breast cancer, thyroid cancer, and renal cancer metastatic to bone. In this article, the physics and radiobiology, as well as a literature update on the use of Radium-223, are provided along with case presentations, aiming at a better appreciation of research data as well as the assimilation of research data into clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85043668144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043668144&partnerID=8YFLogxK
U2 - 10.1155/2016/2568031
DO - 10.1155/2016/2568031
M3 - Review article
C2 - 27774318
AN - SCOPUS:85043668144
SN - 2090-1712
VL - 2016
JO - International Journal of Molecular Imaging
JF - International Journal of Molecular Imaging
M1 - 2568031
ER -